Skip to search formSkip to main contentSkip to account menu

avorelin

Known as: 1-9-Luteinizing Hormone-Releasing Factor (Swine), 6-(2-Methyl-D-Tryptophan)-9-(N-Ethyl-L-Prolinamide)-, 5-Oxo-L-Prolyl-L-Histidyl-L-Tryptophyl-L-Seryl-L-Tyrosyl-2-Methyl-D-Tryptophyl-L-Leucyl-L-Arginyl-N-Ethyl-L-Prolinamide, 5-oxo-Pro-His-Trp-Ser-Tyr-DTrp(2-Me)-Leu-Arg-NH(Et)-prolinamide 
National Institutes of Health

Related topics

Related topics

4 relations
Avorelin Acetateanalogs & derivativesmeterelin

Broader (1)

Proline

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
Pharmacodynamics of a long acting depot preparation of avorelin in patients with prostate cancer. Avorelin Study Group.
1998
1998
Avorelin: Is a 12-monthly LHRH depot implant on the horizon ?
1997
1997
Protracted release of the LHRH agonist avorelin (MF 6001) from two depot formulations in dogs and men
Avorelin is a new superagonist of natural luteinizing-hormone-releasing-hormone. Avorelin has been formulated in high molecular… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)